"For fiscal 2009, we achieved record revenue, earnings and cash flow from operations," stated Dr. Gioacchino De Chirico, Immucor's President and Chief Executive Officer. "Our growth has been driven by the success of our automation strategy combined with the fact that our reagent product offering is necessary to ensure the safety of transfusions."
Selected Product Revenue and Gross Margin ($ amounts in thousands) Revenue Fiscal Q4 2009 Fiscal Q4 2008 Growth Gross Gross Revenue Margin Revenue Margin $ % Traditional reagents $52,149 75.3% $45,274 77.4% $6,875 15% Capture reagents 17,057 84.1% 15,027 86.5% 2,030 14% Instruments 9,058 18.0% 8,312 16.0% 746 9%
Consolidated revenue was $79.0 million in the current year quarter, an increase of approximately $10.4 million, or 15%, over the fourth quarter of fiscal 2008. Revenue in the quarter benefited from both price and volume contributions. Revenue in the quarter was negatively impacted by approximately $3.0 million from foreign currency translation as compared with the fourth quarter of fiscal 2008.
Consolidated gross margin was $55.2 million, or 69.9% of revenue, in the current year quarter compared with $49.4 million, or 72.0% of revenue, in the prior year quarter. During the current year quarter, gross margin was negatively impacted by costs related to the Company's Quality Process I
|SOURCE Immucor, Inc.|
Copyright©2009 PR Newswire.
All rights reserved